- Joined
- 26 October 2006
- Posts
- 327
- Reactions
- 0
I've recently been looking closely for biotech companies with potential to grow long term. This one caught my attention.
Cytopia's goal is to pioneer the development of small molecule therapeutic drugs for diseases such as cancer, cardiovascular and immune disease.
Having commenced operations in 1999, based in Melbourne, it has developed world-leading expertise in kinase biology and integrated a robust structural biology program with medicinal chemistry and drug development.
The Company's products in the pipeline include CYT997 and FMS, which is used for the treatment of cancer; JAK3, which is used for treatment of Chronic organ failure, and JAK2, which is used for the treatment of heart failure and pulmonary hypertension. Recently, they have signed a global license and R&D agreement with Novartis related to their JAK3 therapy.
They claim on their website (http://www.cytopia.com.au) that their "new class of drugs has the potential to achieve total sales measured in the tens of billions of dollars in markets which include solid tumours, leukaemia, lymphoma, multiple myeloma and a range of immune diseases such as rheumatoid arthritis and asthma."
Whilst they have some drug candidates undergoing preclinical assessment prior to entering formal development, their lead anticancer agent, CYT997, has been involved in a Phase I trial in Brisbane, administered intravenously to seriously-ill cancer patients. Application for an extension of this in an oral trial has been sought in the US.
They have collaborations with the following institutions in Australia:
Monash University - X-ray crystallographic studies
Victorian College of Pharmacy - Drug optimization
University of Queensland - Kinase biology
Royal Melbourne Institute of Technology - Conformational analysis of proteins
Baker Heart Research Institute - Cardiovascular models
With the SP now at 0.64, this may provide room for growth over the mid to long term.
Cytopia's goal is to pioneer the development of small molecule therapeutic drugs for diseases such as cancer, cardiovascular and immune disease.
Having commenced operations in 1999, based in Melbourne, it has developed world-leading expertise in kinase biology and integrated a robust structural biology program with medicinal chemistry and drug development.
The Company's products in the pipeline include CYT997 and FMS, which is used for the treatment of cancer; JAK3, which is used for treatment of Chronic organ failure, and JAK2, which is used for the treatment of heart failure and pulmonary hypertension. Recently, they have signed a global license and R&D agreement with Novartis related to their JAK3 therapy.
They claim on their website (http://www.cytopia.com.au) that their "new class of drugs has the potential to achieve total sales measured in the tens of billions of dollars in markets which include solid tumours, leukaemia, lymphoma, multiple myeloma and a range of immune diseases such as rheumatoid arthritis and asthma."
Whilst they have some drug candidates undergoing preclinical assessment prior to entering formal development, their lead anticancer agent, CYT997, has been involved in a Phase I trial in Brisbane, administered intravenously to seriously-ill cancer patients. Application for an extension of this in an oral trial has been sought in the US.
They have collaborations with the following institutions in Australia:
Monash University - X-ray crystallographic studies
Victorian College of Pharmacy - Drug optimization
University of Queensland - Kinase biology
Royal Melbourne Institute of Technology - Conformational analysis of proteins
Baker Heart Research Institute - Cardiovascular models
With the SP now at 0.64, this may provide room for growth over the mid to long term.
